US 12,247,079 B2
Polynucleotides encoding, and method of making, a polypeptide comprising a VHH which binds interleukin-receptor (IL-7R)
Scott Crowe, Cambridge (GB); Mike West, Cambridge (GB); Kevin Roberts, Cambridge (GB); Tim Carlton, Cambridge (GB); Luana Maggiore, Cambridge (GB); Marion Cubitt, Cambridge (GB); Lurdes Duarte, Cambridge (GB); Martyn Symmons, Cambridge (GB); and Keith Ray, Cambridge (GB)
Assigned to SORRISO PHARMACEUTICALS, INC., San Diego, CA (US)
Appl. No. 17/620,030
Filed by SORRISO PHARMACEUTICALS, INC., San Diego, CA (US)
PCT Filed Jun. 19, 2020, PCT No. PCT/GB2020/051496
§ 371(c)(1), (2) Date Dec. 16, 2021,
PCT Pub. No. WO2020/254827, PCT Pub. Date Dec. 24, 2020.
Claims priority of application No. 19181868 (EP), filed on Jun. 21, 2019.
Prior Publication US 2023/0056445 A1, Feb. 23, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2866 (2013.01) [C07K 16/2896 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 15 Claims
 
1. A polynucleotide encoding a polypeptide comprising a VHH,
wherein the VHH comprises:
(a) a complementarity determining region 1 (CDR1) comprising an amino acid sequence as set forth in SEQ ID NO: 1, a complementarity determining region 2 (CDR2) comprising an amino acid sequence as set forth in SEQ ID NO: 2, and a complementarity determining region 3 (CDR3) comprising an amino acid sequence as set forth in SEQ ID NO: 3; or
(b) a CDR1 comprising an amino acid sequence as set forth in SEQ ID NO: 71, a CDR2 comprising an amino acid sequence of any one as set forth in SEQ ID NOs: 72, 73, 74, or 75, and a CDR3 comprising an amino acid sequence of any one as set forth in SEQ ID NOs: 77 or 78,
wherein the VHH binds IL-7R.